The Lancet: BNT162b2 mRNA vaccine is effective against B1.1.7 variants, but prevention still needs to be strengthened

 

The United Kingdom has begun to rapidly launch BNT162b2 mRNA and ChAdOx1 adenovirus vector vaccines in December 2020.

The purpose is to describe the factors related to the coverage of the BNT162b2 and ChAdOx1 new coronavirus- 19 vaccines, and the effectiveness of the BNT162b2 vaccine against all (asymptomatic and symptomatic) infections at an early stage.

The SIREN study is a prospective cohort study of staff (age ≥18 years) working in public hospitals in the UK.

Immunization management

Number of SIREN participants vaccinated by dose, manufacturer, and daily from December 8, 2020 to February 5, 2021 (n=20641)

Number of SIREN participants vaccinated by dose, manufacturer, and daily from December 8, 2020 to February 5, 2021 (n=20641)

23324 participants from 104 sites (all in England) met the inclusion criteria for this analysis and were included in the group.

COVID-19

From December 7, 2020 to February 5, 2021, (A) the whole cohort (n = 23324) and (B) the negative cohort (n = 15121) adjusted hazard ratio of the interval after vaccination.

From December 7, 2020 to February 5, 2021, (A) the whole cohort (n = 23324) and (B) the negative cohort (n = 15121) adjusted hazard ratio of the interval after vaccination.

The study shows that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infections in working-age adults.

The study shows that the BNT162b2 vaccine can prevent both symptomatic and asymptomatic infections in working-age adults.

sciencedirect.

sciencedirect.
com/science/article/pii/S014067362100790X)" target="_blank" rel="noopener">COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study, The Lancet, 2021, ISSN 0140-6736, https://doi.
org/ 10.
1016/S0140-6736(21)00790-X.
Leave a message here